Patents by Inventor Matthias Staufenbiel
Matthias Staufenbiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150374807Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune, responses within the indicated context.Type: ApplicationFiled: July 1, 2015Publication date: December 31, 2015Applicant: Novartis AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Martin Lueoend, Matthias Staufenbiel, Peter Frey
-
Publication number: 20150202281Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: May 30, 2013Publication date: July 23, 2015Applicants: CYTOS BIOTECHNOLOGY AG, NOVARTIS PHARMA AGInventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
-
Publication number: 20140294876Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: December 13, 2013Publication date: October 2, 2014Applicant: NOVARTIS AGInventors: Martin F. BACHMANN, Alain TISSOT, Rainer ORTMANN, Rainer LUEOEND, Matthias STAUFENBIEL, Peter FREY
-
Publication number: 20140079730Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: NOVARTIS AGInventors: Ana GRAF, Matthias STAUFENBIEL, Thomas BLÄTTLER, Paolo PAGANETTI
-
Patent number: 8617566Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A beta-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: May 13, 2013Date of Patent: December 31, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blaettler, Paolo Paganetti
-
Publication number: 20130252889Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the AD-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia.Type: ApplicationFiled: May 13, 2013Publication date: September 26, 2013Applicant: Novartis AGInventors: Ana GRAF, Matthias STAUFENBIEL, Thomas BLÄTTLER, Paolo PAGANETTI
-
Patent number: 8460676Abstract: The present invention relates to uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: December 17, 2010Date of Patent: June 11, 2013Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
-
Publication number: 20120114674Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: April 28, 2011Publication date: May 10, 2012Applicants: NOVARTIS PHARMA AG, CYTOS BIOTECHNOLOGY AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
-
Publication number: 20110086036Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the AType: ApplicationFiled: December 17, 2010Publication date: April 14, 2011Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
-
Patent number: 7867499Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type.Type: GrantFiled: November 3, 2005Date of Patent: January 11, 2011Assignee: Novartis AGInventors: Ana Graf, Matthias Staufenbiel, Thomas Blättler, Paolo Paganetti
-
Publication number: 20090246215Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: October 5, 2007Publication date: October 1, 2009Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Publication number: 20090060899Abstract: The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A?-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the AType: ApplicationFiled: November 3, 2005Publication date: March 5, 2009Inventors: Ana Graf, Matthias Staufenbiel, Thomas Blattler, Paolo Paganetti
-
Publication number: 20080274131Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: January 18, 2008Publication date: November 6, 2008Applicants: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7320793Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: January 22, 2008Assignees: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7279165Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: July 18, 2003Date of Patent: October 9, 2007Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
-
Publication number: 20070142401Abstract: The invention relates to the use of an inhibitor of formula (I), or a pharmaceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta, PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.Type: ApplicationFiled: October 26, 2004Publication date: June 21, 2007Applicant: NOVARTIS AGInventors: Yves Auberson, Graeme Bilbe, Rainer Kuhn, Peter Von Matt, Heinrich Rueger, Matthias Staufenbiel, Jurgen Wagner, Kaspar Zimmermann
-
Publication number: 20040141984Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A&bgr;1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A&bgr;1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: July 18, 2003Publication date: July 22, 2004Applicants: Cytos Biotechnology AG, Novartis Pharma AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Publication number: 20030175711Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: January 18, 2002Publication date: September 18, 2003Applicant: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Publication number: 20030101467Abstract: Animal model involving transgenic manipulation of amyloid precursor protein, useful for testing potential therapeutic agents for the treatment of neurodegenerative disorders, in particular Alzheimer's disease.Type: ApplicationFiled: January 2, 2003Publication date: May 29, 2003Inventors: Bernd Sommer, Matthias Staufenbiel
-
Publication number: 20010016951Abstract: Animal model involving transgenic manipulation of amyloid precursor protein, useful for testing potential therapeutic agents for the treatment of neurodegenerative disorders, in particular Alzheimer's disease.Type: ApplicationFiled: April 25, 2001Publication date: August 23, 2001Inventors: Bernd Sommer, Matthias Staufenbiel